1. Never said it was SOC.
2. "Absolutely no data"? Really? Wrong.
3. Incorrect. Again. DFU's and other diabetes related limb infections in Australia itself, see over 4,000 amputations a year! That's from around '10,000 hospital admissions in Australia for diabetes-related foot ulcers in Australia – many of these end with people having a limb, or part of a limb, amputated' according to Diabetes Australia. But you know better than them I imagine. Current anti-biotics often prove ineffective in DFU's. Its rather why RCE is not the only Australian company conducting formal studies in treatment of them overseas and indeed also in collaborative govt/academic studies. But again, you know better.
Please do next time you see someone in Australia with amputated foot, ask if it was from diabetes and if they were one of those thousands, be sure to give them your insights into DFU amputations NOT being an "unmet need". Just do me a favour and stand close enough so they can easily reach your chin.
Or better still perhaps educate yourself in increasing antimicrobial resistance in DFU cases and increasing rates of amputation thereafter. Here's one of many studies, were your fingers only a little quicker to research, rather than express baseless opinion online:
https://www.sciencedirect.com/science/article/pii/S016882272100156X
"Infections in DFU are capturing the attention of the clinicians because often related to severe discomfort, increased request of medical cares and high risk of healing failure, which may rapidly lead to hospitalization and lower extremities amputation."
"The treatment of infections, including DFI, is becoming increasingly difficult because of the massive consumption of antibiotic drugs which is heavily responsible for emerging antimicrobial resistances."
Predictable personal snipes as usual then @Rykster and as usual no discussion whatsoever of RCE. The chart was cited as a "cut and paste" from the report I sent you, but you obviously can't read.
- Forums
- ASX - By Stock
- RCE
- Ann: Positive Phase II Data from Clinical Trial of R327 Gel
RCE
recce pharmaceuticals ltd
Add to My Watchlist
3.33%
!
31.0¢

Ann: Positive Phase II Data from Clinical Trial of R327 Gel, page-63
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M |
Open | High | Low | Value | Volume |
31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 13550 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 18938 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 13550 | 0.300 |
2 | 34803 | 0.295 |
2 | 50000 | 0.290 |
4 | 131061 | 0.285 |
10 | 251389 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 18938 | 1 |
0.320 | 5000 | 1 |
0.325 | 12600 | 1 |
0.330 | 114230 | 1 |
0.350 | 51319 | 4 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online